How much funding has Preventice Solutions raised?

Preventice Solutions has raised $137.0M in total funding, most recently a Series B round.

Who are Preventice Solutions's investors?

Preventice Solutions's investors include Boston Scientific Corporation, Novo Holdings A/S, Samsung Venture Investment Corporation, Vivo Capital.

When was Preventice Solutions founded?

Preventice Solutions was founded in 2007.

Where is Preventice Solutions headquartered?

Preventice Solutions is headquartered in Minneapolis, Minnesota, United States.

What industry is Preventice Solutions in?

Preventice Solutions operates in Healthcare, Medical Devices.

How many employees does Preventice Solutions have?

Preventice Solutions has 501-1000 employees.

Preventice Solutions

Acquired

Connecting patients and caregivers through mobile cardiac health solutions

Minneapolis, United States · Founded 2007 · $137.0M raised

Healthcare

Medical Devices

Headquarters: Minneapolis, Minnesota
Employees: 501–1000
Founded: 2007
Business Model: B2B

Website: preventicesolutions.com
Total Funding: $137.0M
Last Round: $137.0M Series BJul 2020
Rounds: 1

About

Preventice Solutions is a Minneapolis, Minnesota-based healthcare company that developed a portfolio of mobile cardiac health solutions and remote monitoring services. Its flagship BodyGuardian product line includes wearable cardiac monitors for long-term Holter monitoring, cardiac event monitoring, and mobile cardiac telemetry. The company connects patients at risk of cardiac arrhythmias with physicians via cloud-based infrastructure and machine learning capabilities. Founded in 2007, Preventice was acquired by Boston Scientific Corporation in 2021 for approximately $925 million.

Summary

Preventice Solutions is a Healthcare company based in Minneapolis, United States, founded in 2007. It has raised $137.0M in total across 1 round, most recently a $137.0M Series B round in Jul 2020. Investors include Boston Scientific Corporation, Novo Holdings A/S and Samsung Venture Investment Corporation.